阿替洛尔抗高血压疗效的系统评价:巴西心脏病学会推荐。

IF 1.9
Andréa Araujo Brandão, Cibele Isaac Saad Rodrigues, Wilson Nadruz, Paulo Cesar B Veiga Jardim, Fernando Nobre, Sergio Emanuel Kaiser, Otavio Rizzi Coelho, Fernanda Marciano Consolim Colombo, Leonardo Castro Luna, Andressa Braga, Quenia Dias Morais, Luiz Bortolotto
{"title":"阿替洛尔抗高血压疗效的系统评价:巴西心脏病学会推荐。","authors":"Andréa Araujo Brandão, Cibele Isaac Saad Rodrigues, Wilson Nadruz, Paulo Cesar B Veiga Jardim, Fernando Nobre, Sergio Emanuel Kaiser, Otavio Rizzi Coelho, Fernanda Marciano Consolim Colombo, Leonardo Castro Luna, Andressa Braga, Quenia Dias Morais, Luiz Bortolotto","doi":"10.36660/abc.20250034","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypertension (HTN) is a global public health issue, with high prevalence and a significant impact on cardiovascular morbidity and mortality. Cardioselective beta-blockers, such as atenolol, are widely used in the treatment of HTN, although their indication as first-line therapy remains controversial.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of atenolol in the treatment of primary HTN, compared with other first-line classes of antihypertensive drugs.</p><p><strong>Methods: </strong>A systematic review was conducted based on a research question structured using the PICO format. Randomized clinical trials comparing atenolol with other antihypertensive agents were included. Searches were performed in three international databases. Methodological quality was assessed using the RoB 2 tool, and the certainty of evidence was rated using the GRADE system. The primary composite outcome was the occurrence of major cardiovascular events. Secondary outcomes included all-cause mortality, acute myocardial infarction, and stroke, each analyzed separately.</p><p><strong>Results: </strong>Seven clinical trials met the inclusion criteria. Compared with amlodipine and losartan, atenolol was associated with a slightly higher incidence of cardiovascular events, with low and moderate certainty of evidence, respectively. The combination of hydrochlorothiazide and amiloride demonstrated a greater reduction in cardiovascular events compared to atenolol, although with very low certainty of evidence. Blood pressure (BP) reduction was similar across the compared treatments.</p><p><strong>Conclusions: </strong>Despite the limitations of available evidence, atenolol showed comparable efficacy in BP reduction, with small differences in cardiovascular outcomes favoring other antihypertensive classes. Its use may be considered among the options for combination therapy in the treatment of primary HTN in adults. Other beta-blockers were not evaluated in this systematic review.</p>","PeriodicalId":93887,"journal":{"name":"Arquivos brasileiros de cardiologia","volume":"122 9","pages":"e20250034"},"PeriodicalIF":1.9000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systematic Review on the Efficacy of Atenolol in Antihypertensive Treatment: Recommendation from the Brazilian Society of Cardiology.\",\"authors\":\"Andréa Araujo Brandão, Cibele Isaac Saad Rodrigues, Wilson Nadruz, Paulo Cesar B Veiga Jardim, Fernando Nobre, Sergio Emanuel Kaiser, Otavio Rizzi Coelho, Fernanda Marciano Consolim Colombo, Leonardo Castro Luna, Andressa Braga, Quenia Dias Morais, Luiz Bortolotto\",\"doi\":\"10.36660/abc.20250034\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hypertension (HTN) is a global public health issue, with high prevalence and a significant impact on cardiovascular morbidity and mortality. Cardioselective beta-blockers, such as atenolol, are widely used in the treatment of HTN, although their indication as first-line therapy remains controversial.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of atenolol in the treatment of primary HTN, compared with other first-line classes of antihypertensive drugs.</p><p><strong>Methods: </strong>A systematic review was conducted based on a research question structured using the PICO format. Randomized clinical trials comparing atenolol with other antihypertensive agents were included. Searches were performed in three international databases. Methodological quality was assessed using the RoB 2 tool, and the certainty of evidence was rated using the GRADE system. The primary composite outcome was the occurrence of major cardiovascular events. Secondary outcomes included all-cause mortality, acute myocardial infarction, and stroke, each analyzed separately.</p><p><strong>Results: </strong>Seven clinical trials met the inclusion criteria. Compared with amlodipine and losartan, atenolol was associated with a slightly higher incidence of cardiovascular events, with low and moderate certainty of evidence, respectively. The combination of hydrochlorothiazide and amiloride demonstrated a greater reduction in cardiovascular events compared to atenolol, although with very low certainty of evidence. Blood pressure (BP) reduction was similar across the compared treatments.</p><p><strong>Conclusions: </strong>Despite the limitations of available evidence, atenolol showed comparable efficacy in BP reduction, with small differences in cardiovascular outcomes favoring other antihypertensive classes. Its use may be considered among the options for combination therapy in the treatment of primary HTN in adults. Other beta-blockers were not evaluated in this systematic review.</p>\",\"PeriodicalId\":93887,\"journal\":{\"name\":\"Arquivos brasileiros de cardiologia\",\"volume\":\"122 9\",\"pages\":\"e20250034\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arquivos brasileiros de cardiologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36660/abc.20250034\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arquivos brasileiros de cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36660/abc.20250034","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:高血压(HTN)是一个全球性的公共卫生问题,具有高患病率和对心血管疾病发病率和死亡率的重大影响。心脏选择性β受体阻滞剂,如阿替洛尔,广泛用于治疗HTN,尽管其作为一线治疗的适应症仍存在争议。目的:评价阿替洛尔治疗原发性HTN的疗效和安全性,并与其他一线降压药进行比较。方法:系统回顾采用PICO格式结构化的研究问题。随机临床试验比较阿替洛尔与其他抗高血压药物。在三个国际数据库中进行了搜索。使用RoB 2工具评估方法学质量,使用GRADE系统评估证据的确定性。主要综合结局是主要心血管事件的发生。次要结局包括全因死亡率、急性心肌梗死和中风,分别进行分析。结果:7项临床试验符合纳入标准。与氨氯地平和氯沙坦相比,阿替洛尔与稍高的心血管事件发生率相关,证据确定性分别为低和中等。与阿替洛尔相比,氢氯噻嗪和阿米洛利联合用药可更大程度地减少心血管事件,尽管证据的确定性非常低。血压(BP)的降低在比较治疗中是相似的。结论:尽管现有证据有限,阿替洛尔在降压方面显示出相当的疗效,在心血管结局方面与其他抗高血压药物有微小差异。它的使用可能被认为是成人原发性HTN联合治疗的选择之一。其他受体阻滞剂未在本系统综述中进行评价。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Systematic Review on the Efficacy of Atenolol in Antihypertensive Treatment: Recommendation from the Brazilian Society of Cardiology.

Background: Hypertension (HTN) is a global public health issue, with high prevalence and a significant impact on cardiovascular morbidity and mortality. Cardioselective beta-blockers, such as atenolol, are widely used in the treatment of HTN, although their indication as first-line therapy remains controversial.

Objective: To evaluate the efficacy and safety of atenolol in the treatment of primary HTN, compared with other first-line classes of antihypertensive drugs.

Methods: A systematic review was conducted based on a research question structured using the PICO format. Randomized clinical trials comparing atenolol with other antihypertensive agents were included. Searches were performed in three international databases. Methodological quality was assessed using the RoB 2 tool, and the certainty of evidence was rated using the GRADE system. The primary composite outcome was the occurrence of major cardiovascular events. Secondary outcomes included all-cause mortality, acute myocardial infarction, and stroke, each analyzed separately.

Results: Seven clinical trials met the inclusion criteria. Compared with amlodipine and losartan, atenolol was associated with a slightly higher incidence of cardiovascular events, with low and moderate certainty of evidence, respectively. The combination of hydrochlorothiazide and amiloride demonstrated a greater reduction in cardiovascular events compared to atenolol, although with very low certainty of evidence. Blood pressure (BP) reduction was similar across the compared treatments.

Conclusions: Despite the limitations of available evidence, atenolol showed comparable efficacy in BP reduction, with small differences in cardiovascular outcomes favoring other antihypertensive classes. Its use may be considered among the options for combination therapy in the treatment of primary HTN in adults. Other beta-blockers were not evaluated in this systematic review.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信